venetoclax,ibrutinib
abbvie,roche,janssen
['leukemia', 'venetoclax', 'cll']
#ash22: long-term follow-up data demonstrated a 4-year progression-free #survival of 94.5 percent for #patients with chronic lymphocytic #leukemia #cll treated with first-line #ibrutinib plus #venetoclax: 
Reporting essential clinical news w/ independent analysis for cancer care professionals to optimize patient care & outcomes; oncology/hematology